Histone acetyltransferase inhibitors block neuroblastoma cell growth in vivo

Oncogenesis

Volumn 4, Issue 2, 2015, Pages

  Gajer, J M ^a   Furdas, S D ^a   Grunder A ^b   Gothwal, M ^b   Heinicke, U ^c   Keller, K ^a   Colland, F ^d,h   Fulda, S ^c,e   Pahl, H L ^b   Fichtner, I ^f   Sippl, W ^a,g   Jung, M ^a,e  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c GOETHE UNIVERSITY   (Germany)

^d Hybrigenics SA   (France)

^e GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^f Experimental Pharmacology and Oncology Berlin Buch GmbH   (Germany)

^g MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^h INSTITUT DE RECHERCHES SERVIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE INHIBITOR; ANTINEOPLASTIC AGENT; CASPASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DOXORUBICIN; E1A ASSOCIATED P300 PROTEIN; HISTONE ACETYLTRANSFERASE; HISTONE ACETYLTRANSFERASE GCN5; HISTONE ACETYLTRANSFERASE PCAF; ISOTHIAZOLE DERIVATIVE; LYSINE; PU139; PU141; PYRIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER TISSUE; COMPARATIVE EFFECTIVENESS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SELECTIVITY; FEMALE; HISTONE ACETYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MONOTHERAPY; MOUSE; NEUROBLASTOMA; NEUROBLASTOMA CELL LINE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; TREATMENT RESPONSE; TUMOR XENOGRAFT;

MUS;

EID: 84927767043     PISSN: None     EISSN: 21579024     Source Type: Journal    
DOI: 10.1038/oncsis.2014.51     Document Type: Article

References (61)

1. Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 2009; 325: 834-840.
2. Latham JA, Dent SY. Cross-regulation of histone modifications. Nat Struct Mol Biol 2007; 14: 1017-1024.
3. Strahl BD, Allis CD. The language of covalent histone modifications. Nature 2000; 403: 41-45.
4. Marmorstein R. Protein modules that manipulate histone tails for chromatin regulation. Nat Rev Mol Cell Biol 2001; 2: 422-432.
5. Dyda F, Klein DC, Hickman AB. GCN5-related N-acetyltransferases: A structural overview. Annu Rev Biophys Biomol Struct 2000; 29: 81-103.
6. Liu X, Wang L, Zhao K, Thompson PR, Hwang Y, Marmorstein R et al. The structural basis of protein acetylation by the p300/CBP transcriptional coactivator. Nature 2008; 451: 846-850.
7. Sapountzi V, Cote J. MYST-family histone acetyltransferases: Beyond chromatin. Cell Mol Life Sci 2010; 68: 1147-1156.
8. York B, O'Malley BW. Steroid receptor coactivator (SRC) family: Masters of systems biology. J Biol Chem 2010; 285: 38743-38750.
9. Arrowsmith CH, Bountra C, Fish PV, Lee K, Schapira M. Epigenetic protein families: A new frontier for drug discovery. Nat Rev Drug Discov 2012; 11: 384-400.
10. Marmorstein R. Structure and function of histone acetyltransferases. Cell Mol Life Sci 2001; 58: 693-703.
11. Marmorstein R, Roth SY. Histone acetyltransferases: Function, structure, and catalysis. Curr Opin Genet Dev 2001; 11: 155-161.
12. Sterner DE, Berger SL. Acetylation of histones and transcription-related factors. Microbiol Mol Biol Rev 2000; 64: 435-459.
13. Allis CD, Berger SL, Cote J, Dent S, Jenuwien T, Kouzarides T et al. New nomenclature for chromatin-modifying enzymes. Cell 2007; 131: 633-636.
14. Ellis L, Atadja PW, Johnstone RW. Epigenetics in cancer: Targeting chromatin modifications. Mol Cancer Ther 2009; 8: 1409-1420.
15. Esteller M. Epigenetic changes in cancer. F1000 Biol Rep 2011; 3: 9.
16. Geutjes EJ, Bajpe PK, Bernards R. Targeting the epigenome for treatment of cancer. Oncogene 2012; 31: 3827-3844.
17. Peters AH, Schwaller J. Epigenetic mechanisms in acute myeloid leukemia. Prog Drug Res 2011; 67: 197-219.
18. Wang L, Gural A, Sun XJ, Zhao X, Perna F, Huang G et al. The leukemogenicity of AML1-ETO is dependent on site-specific lysine acetylation. Science 2011; 333: 765-769.
19. Esteller M. Epigenetics in cancer. N Engl J Med 2008; 358: 1148-1159.
20. Santer FR, Hoschele PP, Oh SJ, Erb HH, Bouchal J, Cavarretta IT et al. Inhibition of the acetyltransferases p300 and CBP reveals a targetable function for p300 in the survival and invasion pathways of prostate cancer cell lines. Mol Cancer Ther 2011; 10: 1644-1655.
21. Zhou HJ, Yan J, Luo W, Ayala G, Lin SH, Erdem H et al. SRC-3 is required for prostate cancer cell proliferation and survival. Cancer Res 2005; 65: 7976-7983.
22. Gojis O, Rudraraju B, Alifrangis C, Krell J, Libalova P, Palmieri C et al. The role of steroid receptor coactivator-3 (SRC-3) in human malignant disease. Eur J Surg Oncol 2010; 36: 224-229.
23. Gojis O, Rudraraju B, Gudi M, Hogben K, Sousha S, Coombes RC et al. The role of SRC-3 in human breast cancer. Nat Rev Clin Oncol 2010; 7: 83-89.
24. West AC, Johnstone RW. New and emerging HDAC inhibitors for cancer treatment. J Clin Invest 2014; 124: 30-39.
25. Dekker FJ, Haisma HJ. Histone acetyl transferases as emerging drug targets. Drug Discov Today 2009; 14: 942-948.
26. Huang J, Plass C, Gerhauser C. Cancer chemoprevention by targeting the epigenome. Curr Drug Targets 2011; 12: 1925-1956.
27. Lau OD, Courtney AD, Vassilev A, Marzilli LA, Cotter RJ, Nakatani Y et al. p300/CBPassociated factor histone acetyltransferase processing of a peptide substrate. Kinetic analysis of the catalytic mechanism. J Biol Chem 2000; 275: 21953-21959.
28. Zheng Y, Thompson PR, Cebrat M, Wang L, Devlin MK, Alani RM et al. Selective HAT inhibitors as mechanistic tools for protein acetylation. Methods Enzymol 2004; 376: 188-199.
29. Wu J, Wang J, Li M, Yang Y, Wang B, Zheng YG et al. Small molecule inhibitors of histone acetyltransferase Tip60. Bioorg Chem 2011; 39: 53-58.
30. Kwie FH, Briet M, Soupaya D, Hoffmann P, Maturano M, Rodriguez F et al. New Potent Bisubstrate Inhibitors of Histone Acetyltransferase p300: Design, Synthesis and Biological Evaluation. Chem Biol Drug Des 2010; 77: 86-92.
31. Piaz FD, Vassallo A, Rubio OC, Castellano S, Sbardella G, De Tommasi N et al. Chemical biology of histone acetyltransferase natural compounds modulators. Mol Divers 2011; 15: 401-416.
32. Furdas SD, Shekfeh S, Bissinger EM, Wagner JM, Schlimme S, Valkov V et al. Synthesis and biological testing of novel pyridoisothiazolones as histone acetyltransferase inhibitors. Bioorg Med Chem 2011; 19: 3678-3689.
33. Ghizzoni M, Haisma HJ, Dekker FJ. Reactivity of isothiazolones and isothiazolone-1-oxides in the inhibition of the PCAF histone acetyltransferase. Eur J Med Chem 2009; 44: 4855-4861.
34. Stimson L, Rowlands MG, Newbatt YM, Smith NF, Raynaud FI, Rogers P et al. Isothiazolones as inhibitors of PCAF and p300 histone acetyltransferase activity. Mol Cancer Ther 2005; 4: 1521-1532.
35. Eliseeva ED, Valkov V, Jung M, Jung MO. Characterization of novel inhibitors of histone acetyltransferases. Mol Cancer Ther 2007; 6: 2391-2398.
36. Furdas SD, Shekfeh S, Srinivasaraghavan K, Sippl W, Jung M. Rhodanin carboxylic acids as novel inhibitors of histone acetyltransferases. Med Chem Commun 2012; 3: 305-311.
37. Furdas SD, Kannan S, Sippl W, Jung M. Small molecule inhibitors of histone acetyltransferases as epigenetic tools and drug candidates. Arch Pharm (Weinheim) 2012; 345: 7-21.
38. Bowers EM, Yan G, Mukherjee C, Orry A, Wang L, Holbert MA et al. Virtual ligand screening of the p300/CBP histone acetyltransferase: Identification of a selective small molecule inhibitor. Chem Biol 2010; 17: 471-482.
39. Trisciuoglio D, Ragazzoni Y, Pelosi A, Desideri M, Carradori S, Gabellini C et al. CPTH6, a thiazole derivative, induces histone hypoacetylation and apoptosis in human leukemia cells. Clin Cancer Res 18: 475-486.
40. Selvi BR, Pradhan SK, Shandilya J, Das C, Sailaja BS, Shankar GN et al. Sanguinarine interacts with chromatin, modulates epigenetic modifications, and transcription in the context of chromatin. Chem Biol 2009; 16: 203-216.
41. Arif M, Vedamurthy BM, Choudhari R, Ostwal YB, Mantelingu K, Kodaganur GS et al. Nitric oxide-mediated histone hyperacetylation in oral cancer: Target for a water-soluble HAT inhibitor, CTK7A. Chem Biol 2010; 17: 903-913.
42. Wright SW, Petraitis JJ, Batt DG, Corbett RL, Di Meo SV, Freimark B et al. Metabolism resistant isothiazolone inhibitors of cartilage breakdown. Bioorg Med Chem 1995; 3: 227-234.
43. Wisastra R, Ghizzoni M, Maarsingh H, Minnaard AJ, Haisma HJ, Dekker FJ et al. Isothiazolones; thiol-reactive inhibitors of cysteine protease cathepsin B and histone acetyltransferase PCAF. Org Biomol Chem 2011; 9: 1817-1822.
44. Keller K, Jung M. Histone Deacetylase (HDAC) Inhibitors In Recent Clinical Trials for Cancer Therapy. In: Lübbert M, Jones P (eds). Epigenetic Therapy of Cancer. Springer, Springer, Berlin, Heidelberg, Germany, 2014.
45. Yoo SY, Kim JS, Sung KW, Jeon TY, Choi JY, Moon SH et al. The degree of tumor volume reduction during the early phase of induction chemotherapy is an independent prognostic factor in patients with high-risk neuroblastoma. Cancer 2012; 119: 656-664.
46. Lautz TB, Jie C, Clark S, Naiditch JA, Jafari N, Qiu YY et al. The effect of vorinostat on the development of resistance to doxorubicin in neuroblastoma. PLoS ONE 2012; 7: E40816.
47. Lautz TB, Naiditch JA, Clark S, Chu F, Madonna MB. Efficacy of class I and II vs class III histone deacetylase inhibitors in neuroblastoma. J Pediatr Surg 2012; 47: 1267-1271.
48. Sanchez E, Shen J, Steinberg J, Li M, Wang C, Bonavida B et al. The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo. Leuk Res 2011; 35: 373-379.
49. Yang C, Choy E, Hornicek FJ, Wood KB, Schwab JH, Liu X et al. Histone deacetylase inhibitor (HDACI) PCI-24781 potentiates cytotoxic effects of doxorubicin in bone sarcoma cells. Cancer Chemother Pharmacol 2011; 67: 439-446.
50. Fichtner I, Rolff J, Soong R, Hoffmann J, Hammer S, Sommer A et al. Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers. Clin Cancer Res 2008; 14: 6456-6468.
51. Manzo F, Tambaro FP, Mai A, Altucci L. Histone acetyltransferase inhibitors and preclinical studies. Expert Opin Ther Pat 2009; 19: 761-774.
52. Clerici F, Gelmi ML, Yokoyama K, Pocar D, Van Voorhis WC, Buckner FS et al. Isothiazole dioxides: Synthesis and inhibition of Trypanosoma brucei protein farnesyltransferase. Bioorg Med Chem Lett 2002; 12: 2217-2220.
53. Hayakawa N, Nozawa K, Ogawa A, Kato N, Yoshida K, Akamatsu K et al. Isothiazolone derivatives selectively inhibit telomerase from human and rat cancer cells in vitro. Biochemistry 1999; 38: 11501-11507.
54. Trevillyan JM, Chiou XG, Ballaron SJ, Tang QM, Buko A, Sheets MP et al. Inhibition of p56(lck) tyrosine kinase by isothiazolones. Arch Biochem Biophys 1999; 364: 19-29.
55. Vernarecci S, Tosi F, Filetici P. Tuning acetylated chromatin with HAT inhibitors: A novel tool for therapy. Epigenetics 2010; 5: 105-111.
56. Colland F, Formstecher E, Jacq X, Reverdy C, Planquette C, Conrath S et al. Smallmolecule inhibitor of USP7/HAUSP ubiquitin protease stabilizes and activates p53 in cells. Mol Cancer Ther 2009; 8: 2286-2295.
57. Liu Y, Lashuel HA, Choi S, Xing X, Case A, Ni J et al. Discovery of inhibitors that elucidate the role of UCH-L1 activity in the H1299 lung cancer cell line. Chem Biol 2003; 10: 837-846.
58. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990; 82: 1107-1112.
59. Voigt W. Sulforhodamine B assay and chemosensitivity. Methods Mol Med 2005; 110: 39-48.
60. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27-55.
61. Carneiro VC, De Abreu da Silva IC, Torres EJ, Caby S, Lancelot J, Vanderstraete M et al.Epigenetic changes modulate schistosome egg formation and are a novel target for reducing transmission of schistosomiasis. PLoS Pathog 2014; 10: E1004116.